MacroGenics, Inc. (NASDAQ:MGNX) SVP Jon Marc Wigginton sold 10,000 shares of the company’s stock in a transaction on Wednesday, October 25th. The shares were sold at an average price of $20.00, for a total value of $200,000.00. Following the completion of the transaction, the senior vice president now directly owns 40,000 shares in the company, valued at $800,000. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

MacroGenics, Inc. (NASDAQ:MGNX) traded up 0.21% during midday trading on Thursday, hitting $19.04. The stock had a trading volume of 125,585 shares. The stock’s market cap is $700.63 million. MacroGenics, Inc. has a 12 month low of $14.36 and a 12 month high of $31.85. The stock has a 50 day moving average of $17.66 and a 200 day moving average of $18.14.

MacroGenics (NASDAQ:MGNX) last issued its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($1.14) earnings per share for the quarter, missing the consensus estimate of ($1.05) by ($0.09). MacroGenics had a negative return on equity of 56.81% and a negative net margin of 1,216.51%. The company had revenue of $1.70 million for the quarter, compared to analyst estimates of $15.82 million. During the same quarter in the previous year, the company posted $1.12 earnings per share. The company’s quarterly revenue was down 97.9% compared to the same quarter last year. Analysts expect that MacroGenics, Inc. will post ($4.42) EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This report was published by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another domain, it was stolen and reposted in violation of U.S. and international copyright and trademark laws. The correct version of this report can be accessed at https://www.americanbankingnews.com/2017/10/26/macrogenics-inc-mgnx-svp-sells-200000-00-in-stock.html.

A number of institutional investors and hedge funds have recently modified their holdings of MGNX. Wells Fargo & Company MN grew its position in MacroGenics by 100.8% during the first quarter. Wells Fargo & Company MN now owns 48,200 shares of the biopharmaceutical company’s stock worth $896,000 after buying an additional 24,198 shares during the period. Swiss National Bank grew its position in MacroGenics by 5.5% during the first quarter. Swiss National Bank now owns 46,000 shares of the biopharmaceutical company’s stock worth $856,000 after buying an additional 2,400 shares during the period. Ameriprise Financial Inc. grew its position in MacroGenics by 1.0% during the first quarter. Ameriprise Financial Inc. now owns 49,059 shares of the biopharmaceutical company’s stock worth $912,000 after buying an additional 485 shares during the period. Stifel Financial Corp grew its position in MacroGenics by 7.8% during the first quarter. Stifel Financial Corp now owns 20,155 shares of the biopharmaceutical company’s stock worth $370,000 after buying an additional 1,450 shares during the period. Finally, American International Group Inc. grew its position in MacroGenics by 7.1% during the first quarter. American International Group Inc. now owns 19,632 shares of the biopharmaceutical company’s stock worth $365,000 after buying an additional 1,300 shares during the period. Institutional investors own 84.63% of the company’s stock.

Several equities research analysts have weighed in on MGNX shares. Cowen and Company reaffirmed a “buy” rating on shares of MacroGenics in a research report on Wednesday. BidaskClub downgraded MacroGenics from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 12th. Morgan Stanley cut their price target on MacroGenics from $22.00 to $21.00 and set an “equal weight” rating on the stock in a research report on Monday, August 7th. Zacks Investment Research raised MacroGenics from a “sell” rating to a “hold” rating in a research report on Tuesday, October 10th. Finally, ValuEngine downgraded MacroGenics from a “sell” rating to a “strong sell” rating in a research report on Thursday, August 3rd. Three equities research analysts have rated the stock with a sell rating, three have issued a hold rating and nine have given a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $30.30.

About MacroGenics

MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies.

Receive News & Ratings for MacroGenics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.